Therapeutic Equivalence (TE)
Drug products classified as therapeutically equivalent can be substituted with the full expectation that the substituted product will produce the same clinical effect and safety profile as the prescribed product. Drug products are considered to be therapeutically equivalent only if they meet these criteria:
- they are pharmaceutical equivalents (contain the same active ingredient(s); dosage form and route of administration; and strength.)
- they are assigned by FDA the same therapeutic equivalence codes starting with the letter "A ." To receive a letter "A", FDA
- designates a brand name drug or a generic drug to be the Reference Listed Drug (RLD).
- assigns therapeutic equivalence codes based on data that a drug sponsor submits in an ANDA to scientifically demonstrate that its product is bioequivalent (i.e., performs in the same manner as the Reference Listed Drug).
Featured Products
Best Practices in Quality and Compliance Management
Price: $70.00
Price: $70.00
Immunogenicity To Biologics: Processes, Impact On Efficacy And Safety, and Management Strategy
Processes and effects of immunogenicity to biologics - screening methodologies - regulatory mandates - commercial repercussions of unwanted immune responses
Processes and effects of immunogenicity to biologics - screening methodologies - regulatory mandates - commercial repercussions of unwanted immune responses
Differences in GMP Requirements between Drugs and Biologics
Biologics regulations - drug regulations - differences in GMP requirements
Biologics regulations - drug regulations - differences in GMP requirements
Quality Expectations for Drugs and Biologics during Early Development: Phase 2
Phase 2 FDA Guidance Documents - QC studies - CMC quality elements - Common Technical Document CTD - Biologics License Application BLA - New Drug Application NDA
Phase 2 FDA Guidance Documents - QC studies - CMC quality elements - Common Technical Document CTD - Biologics License Application BLA - New Drug Application NDA